Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Freeline Therapeutics Holdings plc

Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is currently advancing FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Freeline has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201. Freeline is headquartered in the UK and has operations in the United States.

Freeline

Today, on the start of #BlackHistoryMonth, our Chief People Officer Nicole Jones, SPHR reflects on the contributions of Black leaders and recognizes those in her own life who have supported her career.
 
Throughout the month, we look forward to celebrating the rich cultural heritage of the Black community and recognizing their triumphs in the face of adversity.

#MLKDay is an opportunity for us to honor the legacy of Dr. Martin Luther King Jr. and reflect on how we can carry his legacy forward.
 
This year, The King Center’s theme is “It Starts With Me.”
 
Today and every day, we have the opportunity to embrace Dr. King’s values by opening our hearts and minds, showing courage and compassion, and being steadfast in our pursuit for a kinder, more equitable and peaceful world.

From virtual meetups to in-person team dinners, our employees across the UK and US enjoyed some holiday festivities and fun this month!
 
Our virtual “speed networking” event gave employees across our sites a chance to connect socially in smaller groups, as we continue to foster a strong, collaborative, and united culture.
 
This holiday season and new year, we want to extend a special thanks to the patient advocacy groups and Gaucher community who continue to show resilience and support for one another, as well as for the hard work and dedication of our entire team.
 
From all of us at Freeline, we wish you a happy holiday and great start to the new year!

Join us Wednesday, November 29, for an educational webinar on two #Gaucher disease type 1 gene therapy trials currently enrolling participants including our Phase 1/2 GALILEO-1 study.
 
We look forward to discussing these opportunities alongside Prevail Therapeutics and in partnership with the Gaucher Community Alliance and International Gaucher Alliance.
 
Register here: https://lnkd.in/gi73XstY

This week we express our gratitude for our Freeline team and their commitment to science and innovation, and to the Gaucher community whose resiliency continues to inspire our work day in and day out.
 
We hope everyone has a safe and happy Thanksgiving holiday!

Last week Aviva Rosenberg, JD,  co-founder and co-president of the Gaucher Community Alliance joined us to share her perspective on the importance of raising awareness of #gaucherdisease.

Thank you, Aviva, for your time and thoughtful insights!

#rarediseaseawareness

This week, Freeline employees from across the UK and US participated in our first Global Day of Service.
 
- Our teammates in Stevenage sorted, counted and boxed nearly 8,000 books for Kenyan libraries at Just be a Child.
 
- The Boston team volunteered at Community Servings, where they helped prep medically tailored, scratch-made meals for approximately 2,400 chronically and critically ill individuals.
 
- Our employees in New York volunteered at GMHC where they assisted clients and served nearly 180 hot meals.
 
Thank you to all who participated and helped to support our local communities!

That’s a wrap on #ESGCT2023! Thank you to the conference organizers and those attended our oral presentation.

#gaucherdisease

Today Freeline will share new clinical data from its Phase 1/2 clinical trial evaluating FLT201, its novel AAV #genetherapy candidate for #gaucher disease in an oral presentation at the European Society of Gene and Cell Therapy’s annual congress.

Learn more about the study here: https://lnkd.in/gaUunUbv

#ESGCT2023

Gaucher disease is a rare, inherited disorder that can cause debilitating and chronic symptoms for patients.

This #GaucherAwarenessMonth, we’re committed to raising awareness of the burden of the disease and the need for new treatment options. 

#gaucher #gaucherawareness #rarediseases #rarediseaseawareness

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22
account payables	1.62M -	5.82M 259.30%	8.09M 39.13%	5.19M 35.91%	10.06M 93.91%
accumulated other comprehensive income loss	-2.85M -	-3.00M 5.41%	9.34M 411.50%	9.47M 1.39%	-3.15M 133.27%
cash and cash equivalents	16.05M -	73.70M 359.17%	229.97M 212.03%	117.66M 48.84%	47.28M 59.82%
cash and short term investments	16.05M -	73.70M 359.17%	229.97M 212.03%	117.66M 48.84%	47.28M 59.82%
common stock
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets	38K -	43K 13.16%	23K 46.51%	8K 65.22%
intangible assets			23K -	8K 65.22%
inventory	616K -	842K 36.69%	3.08M 265.80%	6.42M 108.38%	17.64M 174.91%
long term debt					3.26M -
long term investments
net debt	-16.05M -	-73.70M 359.17%	-229.97M 212.03%	-117.66M 48.84%	-41.35M 64.85%
net receivables	8.99M -	11.50M 27.94%	16.11M 40.09%	2.21M 86.28%	1.23M 44.37%
other assets
other current assets	431K -	3.00M 595.82%	9.01M 200.37%	2.00M 77.79%	1.47M 26.34%
other current liabilities	7.54M -	6.62M 12.29%	10.72M 61.99%	15.50M 44.58%	18.25M 17.73%
other liabilities
other non current assets	275K -	1.03M 274.18%	1.80M 75.41%	2.92M 61.72%	3.46M 18.53%
other non current liabilities
othertotal stockholders equity	91.57M -	207.62M 126.73%	456.29M 119.77%	467.21M 2.39%	500.92M 7.21%
preferred stock	1K -	1K 0%	155K 15,400%	137K 11.61%
property plant equipment net	5.73M -	7.27M 26.87%	8.61M 18.37%	9.91M 15.08%	15.02M 51.64%
retained earnings	-65.76M -	-119.67M 81.98%	-215.99M 80.49%	-356.38M 65.00%	-445.35M 24.97%
short term debt					2.66M -
short term investments
tax assets					533K -
tax payables
total assets	32.13M -	97.39M 203.07%	268.61M 175.81%	141.13M 47.46%	86.64M 38.61%
total current assets	26.09M -	89.05M 241.32%	258.18M 189.94%	128.29M 50.31%	67.63M 47.29%
total current liabilities	9.16M -	12.43M 35.70%	18.81M 51.29%	20.68M 9.95%	30.97M 49.71%
total debt					5.92M -
total investments
total liabilities	9.16M -	12.43M 35.70%	18.81M 51.29%	20.68M 9.95%	34.23M 65.48%
total liabilities and stockholders equity	32.13M -	97.39M 203.07%	268.61M 175.81%	141.13M 47.46%	86.64M 38.61%
total non current assets	6.04M -	8.34M 38.03%	10.44M 25.07%	12.83M 22.97%	19.01M 48.16%
total non current liabilities					3.26M -
total stockholders equity	22.97M -	84.96M 269.84%	249.80M 194.03%	120.44M 51.79%	52.41M 56.48%

LIFE:FREELINE

Freeline

Last Close

6.48

16/02 20:37

Market Cap

28.28M

Beta: -

Volume Today

5.35K

Avg: -

Preview